Though the expression of ALDH1, a stem cell marker 33, increased after invivoPen or PAM treatment, ALDH1-high spots exhibited increased cell death, suggesting that cells with higher cancer stemness have higher sensitivities to CAP treatment. Here, ALDH1A1 is linked to cancer.